Welcome to our dedicated page for Jazz Pharmaceuticals news (Ticker: $JAZZ), a resource for investors and traders seeking the latest updates and insights on Jazz Pharmaceuticals stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Jazz Pharmaceuticals's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Jazz Pharmaceuticals's position in the market.
Jazz Pharmaceuticals plc (Nasdaq: JAZZ) will participate in the BofA Securities 2024 Global Health Care Conference on May 15, 2024, in Las Vegas. The fireside chat will be held at 10:00 a.m. PT / 1:00 p.m. ET / 6:00 p.m. IST. An audio webcast will be available via the Investors section of the Jazz Pharmaceuticals website.
Jazz Pharmaceuticals plc is a global biopharma company focused on developing life-changing medicines for serious diseases. The company has a diverse portfolio of treatments for sleep disorders, epilepsy, and cancer. Jazz Pharmaceuticals is headquartered in Dublin, Ireland, with a commitment to serving patients worldwide.
Jazz Pharmaceuticals reported a 12% year-over-year revenue increase driven by key growth drivers Xywav, Epidiolex, and Rylaze. They submitted zanidatamab BLA for 2L BTC, expect to launch in 2025, and affirmed 2024 total revenue guidance at $4.0 to $4.2 billion. Various pipeline catalysts and near-term data releases are anticipated. Financials showed a decrease in Xyrem net product sales, an increase in Epidiolex/Epidyolex net product sales, and Rylaze/Enrylaze net product sales. The company provided extensive updates on their key commercial products, pipeline highlights, financial highlights, and 2024 financial guidance.
Jazz Pharmaceuticals is focusing on taking actions to positively impact the planet during Earth Month. They are reflecting on steps to become more conscious of their actions and promoting sustainable practices. For more information, read their Corporate Sustainability and Social Impact Report.
